Brussels (Belgium), 13 July 2018 – 20:00 (CEST) – regulated information
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 9 July 2018 from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.).
BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights and equivalent financial instruments by its affiliates, its shareholding in UCB SA has increased and has crossed the 5% threshold on 6 July 2018.
On 6 July 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 8 982 056 UCB shares with voting rights (versus 8 780 237 shares in its previous notification dated 3 July 2018), representing 4.62% of the total number of shares issued by the company (194 505 658) (versus 4.51% in the notification dated 3 July 2018) as well as 803 011 equivalent financial instruments (versus 779 207 in its previous notification dated 3 July 2018) representing 0.41% of the total number of shares issued by the company (versus 0.40% in the notification dated 3 July 2018).
2. Content of the notification
The transparency notification dated 9 July 2018 includes the following information:
- Reason for the notification: Acquisition or disposal of voting securities or voting rights.
- Notification by: A parent undertaking or a controlling person.
- Person subject to the notification requirement:
- Date on which the threshold is crossed: 6 July 2018.
- Threshold crossed (in %): 5%
- Denominator: 194 505 658.
- Notified details:
- Chain of controlled undertakings through which the holding is effectively held:
Please see the full chain of control in the PDF which is sent separately to this notification.
- Additional information:
The disclosure obligation arose due to total voting rights for BlackRock, Inc. going above 5%.
3. Further information
This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.
Investor Relations, UCB
T +32 2 559 94 14, email@example.com
Investor Relations, UCB
T +32 2 559 95 88, firstname.lastname@example.org
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Stay up-to-date on the latest news and information from UCB